Welcome to our dedicated page for Biodesix news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix stock.
Biodesix, Inc. (BDSX) is a trailblazing diagnostic solutions company specialized in the development and commercialization of blood-based molecular diagnostic tests. These tests advance the standard of care in oncology by providing invaluable data to help patients and their doctors make more informed decisions based on a patient's unique molecular profile. This approach is at the heart of precision medicine, aiming to provide the right treatment to the right patient at the right time.
The company is particularly focused on lung disease and operates in a single segment dedicated to providing diagnostic testing services. Biodesix partners with pharmaceutical companies to develop and commercialize diagnostic tests that accelerate drug development pipelines and bring effective therapies to the market.
Among its notable products are two commercialized tests, VeriStrat® and GeneStrat™, which offer rapid results within 72 hours and do not require tissue samples. These tests enable quicker and more precise treatment decisions, facilitating optimal patient care.
Biodesix's revenue streams come from two primary sources: providing diagnostic testing services related to blood-based lung and COVID-19 tests, and offering biopharmaceutical companies services for diagnostic research, clinical trial testing, and companion diagnostics development. These services are generally performed outside the clinical setting and are governed by individual contracts with third parties.
Recently, Biodesix has been in the news for various significant developments. The latest updates highlight the company's ongoing projects, partnerships, and achievements in the diagnostic field. Stay tuned for more updates as Biodesix continues to innovate in precision medicine and diagnostic solutions.
Biodesix, Inc. (NASDAQ: BDSX) reported significant findings presented at the IASLC World Conference on Lung Cancer, emphasizing the role of genomic and proteomic testing in improving treatment outcomes for lung cancer patients.
Key studies included a blood-based proteomic test predicting survival in non-small cell lung cancer patients undergoing immunotherapy, and the rapid turnaround of a KRAS test that allows for expedited treatment decisions. CEO Scott Hutton highlighted the goal of enhancing patient outcomes while reducing healthcare costs.
Biodesix, a data-driven diagnostic solutions company, will present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on
The event will be available for live webcast and replay on the company's website. Biodesix specializes in lung disease diagnostics, with a portfolio that includes non-invasive tests and advanced AI integration, supporting rapid treatment decisions for lung cancer patients.
Biodesix, Inc. (BDSX) reported a strong second quarter for 2021, highlighting 180% growth in total revenue to $11.9 million, driven by a 109% increase in core lung diagnostic revenue. The company anticipates ongoing growth supported by its expanding sales force and emerging from the pandemic. Notably, COVID-19 testing revenue surged 345%, although a sequential decline was noted as vaccinations progressed. Despite a 38% rise in net loss to $11.4 million, Biodesix maintains a robust cash position of $56.3 million as of June 30, 2021.
Biodesix (Nasdaq: BDSX) announced its CEO, Scott Hutton, will present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 12:30 PM ET. The presentation will be available for live streaming and replay on the company's website. Biodesix focuses on innovative diagnostic solutions for lung diseases, offering non-invasive tests and leveraging AI technology. The company has developed tests for COVID-19, including SARS-CoV-2 ddPCR™, and its lung cancer strategies help expedite treatment decisions. More details can be found at biodesix.com.
Biodesix (Nasdaq: BDSX) will release its second-quarter financial results on August 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a business update. The company is recognized for developing diagnostic tests for lung diseases, including recent contributions to COVID-19 diagnostics. Biodesix's innovative tests aid in critical treatment decisions and cancer risk assessments, leveraging advancements in artificial intelligence.
Biodesix (Nasdaq: BDSX) announced a webinar in collaboration with Seer to discuss proteomics trends in biomarker discovery on June 22, 2021. The event features experts discussing the Seer Proteograph™ Product Suite, which enhances plasma protein analysis to support Biodesix's diagnostic tests. As a leader in lung disease diagnostics, Biodesix combines proteomic and genomic insights through AI. They have launched several COVID-19 tests and provide rapid lung cancer treatment decision support through their innovative testing strategies.
Biodesix, Inc. (BDSX) has announced the commercial launch of its SARS CoV-2 Neutralization Antibody Test (cPass™), authorized by the FDA for emergency use. This test detects neutralizing antibodies against SARS-CoV-2's receptor binding domain, indicating immunity from prior infection or vaccination. It is particularly significant for immunocompromised individuals, providing crucial data for healthcare providers for better management. The launch of the cPass test emphasizes Biodesix's commitment to addressing lung disease diagnostics and support for patient treatment decisions.
Biodesix (BDSX) has announced a strategic partnership with Datavant to enhance lung cancer diagnostics. This collaboration enables Biodesix to anonymize its lung cancer biobank, consisting of 150,000 samples, and link it to real-world data sets securely. The partnership aims to improve clinical decision-making and inform biopharma companies throughout the product development cycle. Biodesix's ongoing INSIGHT study will also contribute treatment decisions and outcomes data, providing a comprehensive view of patient health while ensuring patient privacy.
Biodesix (BDSX) and the Addario Lung Cancer Medical Institute announced the enrollment of the first patient in the BEACON-Lung study, aimed at evaluating biomarkers for predicting survival in advanced-stage non-small cell lung cancer (NSCLC) patients. This study will utilize Biodesix's Primary Immune Response (PIR) test to identify patients who may benefit from PD-1/PD-L1 therapy. Targeting 390 patients across nearly 10 sites, the study will enhance understanding of treatment options and improve survival rates for NSCLC patients.
FAQ
What is the current stock price of Biodesix (BDSX)?
What is the market cap of Biodesix (BDSX)?
What does Biodesix, Inc. specialize in?
What are some of Biodesix's key products?
How does Biodesix contribute to precision medicine?
What services does Biodesix provide to biopharmaceutical companies?
What are Biodesix's primary revenue sources?
How quickly can Biodesix's tests provide results?
Does Biodesix require tissue samples for its tests?
What recent achievements has Biodesix made?
Is Biodesix focused solely on oncology diagnostics?
What is the ticker symbol for Biodesix, Inc. on the stock market?
